AI assistant
Sending…
bioAffinity Technologies, Inc. — Director's Dealing 2024
Sep 20, 2024
35439_dirs_2024-09-20_022f24f3-c573-4e7c-920b-c55036f45434.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-09-16
Reporting Person: Edwards James Michael (Interim CFO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, par value $0.007 | 13956 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants (right to buy) | $3.0625 | 2027-09-01 | Common Stock (5876) | Direct | |
| Non-tradeable Warrants (right to buy) | $3.0625 | 2027-09-01 | Common Stock (6120) | Direct | |
| Warrant (right to buy) | $5.25 | 2026-11-21 | Common Stock (1903) | Direct | |
| Warrant (right to buy) | $5.25 | 2027-07-20 | Common Stock (761) | Direct |
More from bioAffinity Technologies, Inc.
Regulatory Filings
2026
Jun 2
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 12
Earnings Release
2026
May 8
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 7
Investor Presentation
2026
Mar 26